Published in Therap Adv Gastroenterol on April 19, 2016
Can probiotics benefit children with autism spectrum disorders? World J Gastroenterol (2016) 0.75
Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 0.75
Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr (2017) 0.75
Immunomodulatory Activities of a Fungal Protein Extracted from Hericium erinaceus through Regulating the Gut Microbiota. Front Immunol (2017) 0.75
A core gut microbiome in obese and lean twins. Nature (2008) 52.30
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57
Structure, function and diversity of the healthy human microbiome. Nature (2012) 30.40
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Enterotypes of the human gut microbiome. Nature (2011) 24.36
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 20.60
Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell (2006) 18.83
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Induction of colonic regulatory T cells by indigenous Clostridium species. Science (2010) 16.71
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 14.18
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A (2010) 11.21
Diet rapidly and reproducibly alters the human gut microbiome. Nature (2013) 11.04
Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut (2005) 10.95
Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A (2010) 9.57
Microbial influences in inflammatory bowel diseases. Gastroenterology (2008) 9.20
Diversity, stability and resilience of the human gut microbiota. Nature (2012) 9.09
A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med (2013) 8.94
The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013) 8.53
Gut microbiota in health and disease. Physiol Rev (2010) 7.76
Host-gut microbiota metabolic interactions. Science (2012) 7.73
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A (2008) 7.43
The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe (2014) 7.43
The gut flora as a forgotten organ. EMBO Rep (2006) 7.42
Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics (2006) 7.40
Intestinal mucosal barrier function in health and disease. Nat Rev Immunol (2009) 7.15
Microbial community profiling for human microbiome projects: Tools, techniques, and challenges. Genome Res (2009) 7.12
Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut (2009) 6.50
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature (2012) 5.63
Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol (2005) 5.62
Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol (2010) 5.57
Guidelines for the management of inflammatory bowel disease in adults. Gut (2011) 5.42
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science (2012) 5.34
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology (2010) 5.29
Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol (2011) 4.57
The keystone-pathogen hypothesis. Nat Rev Microbiol (2012) 4.18
High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut (2008) 4.10
Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis (2011) 4.09
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol (2004) 4.05
The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol (2012) 3.88
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology (2015) 3.84
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome (2013) 3.56
Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol (2010) 3.32
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut (2013) 3.26
Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial. Lancet (1993) 3.19
Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell (2015) 3.13
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology (2015) 3.12
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature (2015) 3.06
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol (2007) 3.00
Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut (2009) 2.98
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology (2011) 2.90
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
Control of pathogens and pathobionts by the gut microbiota. Nat Immunol (2013) 2.84
The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol (2012) 2.83
The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology (2014) 2.73
Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr (2001) 2.70
Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol (2014) 2.65
Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology (2003) 2.62
Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis (2011) 2.62
Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis (2014) 2.59
Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 2.57
The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol (2014) 2.55
Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil (2012) 2.49
A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr (2012) 2.47
Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol (2011) 2.39
The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 2.37
The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2009) 2.35
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol (2009) 2.34
Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut (2013) 2.32
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol (2006) 2.24
Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut (1991) 2.24
Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol (2011) 2.19
Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol Ecol (2005) 2.18
Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut (2005) 2.17
Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2011) 2.14
Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr (2010) 2.13
Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther (2011) 2.12
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics (2012) 2.04
Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut (2002) 1.96
Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis (2014) 1.96
Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr (2011) 1.96
Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2011) 1.95
Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut (2013) 1.93
Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.91
Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev (2013) 1.91